
In
addition, surge in the aged populace and increasing number of surgeries
associated with them such as orthopedic surgeries, cardiac surgeries, etc. will
drive the market growth in the years to come. Also, benefits of minimally
invasive surgeries over conventional surgeries, such as shorter hospital stay,
low tissue damage, less scaring, and lesser pain is expected to drive the
market growth.
On
the other hand, absence of proper reimbursement scenario, lack of trained
surgeons in developing countries, and improper sterilization methods may hinder
the market growth over the forecast period.
In
May 2017, Medtronic plc received the Food and Drug Administration (FDA) approval
and introduced the Resolute Onyx Drug-Eluting Stent
(DES). It supports the gold standard efficacy and safety of DES technique. Subsequently, the company received
approval from the USFDA for the launch of Core Valve Evolut PRO valve, designed
for symptomatic patients who have gone through open heart surgeries.
The
emerging trend in the minimally invasive surgical instruments is increasing
demand for medical tourism and increase in number of surgical procedures
performed in developing countries such as India, China, Brazil, South Korea,
Thailand, Mexico, and Malaysia.
North
America became a dominant segment in the region in 2017 owing to the rising
geriatric population and high rate of unintentional injuries.
Stryker;
Medtronic; Abbott; Smith & Nephew; NuVasive, Inc.; Zimmer Biomet; Intuitive
Surgical, Inc; and CONMED are some of the leading players in the minimally
invasive surgical instruments market
Access
a Press Release on Minimally Invasive Surgical Instruments Market @ https://www.grandviewresearch.com/press-release/global-minimally-invasive-surgical-instruments-market
No comments:
Post a Comment